Clinical Trial Update: A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating hematopoietic stem cells transduced with Lenti-D lentiviral vector for cerebral adrenoleukodystrophy (CALD) has completed with posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Adrenoleukodystrophy

Drugs mentioned

• Lenti-D (elivaldogene autotemcel)

Snippet

Sponsor: Genetix Biotherapeutics Inc. | Conditions: Cerebral Adrenoleukodystrophy (CALD) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-04-25